Comparative Pharmacology
Head-to-head clinical analysis: METHYCLOTHIAZIDE versus TRICHLORMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYCLOTHIAZIDE versus TRICHLORMETHIAZIDE.
METHYCLOTHIAZIDE vs TRICHLORMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide-like diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reduces peripheral vascular resistance.
Inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water.
2.5-10 mg orally once daily.
2-4 mg orally once daily; maximum 4 mg/day.
None Documented
None Documented
Terminal elimination half-life: ~40 hours (range 30-50 h); due to extensive tubular reabsorption, half-life is prolonged in renal impairment and elderly, allowing once-daily dosing
Clinical Note
moderateMethyclothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin."
Clinical Note
moderateTrichlormethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin."
Clinical Note
moderateMethyclothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin."
Clinical Note
moderateTerminal elimination half-life is approximately 2-6 hours (average 3.5 h); clinical context: short half-life necessitates once or twice daily dosing for sustained diuresis.
Primarily renal (70-80% as unchanged drug via tubular secretion and glomerular filtration); minor biliary/fecal (<10%)
Primarily renal (tubular secretion); ~70% excreted unchanged in urine; minor biliary/fecal (<10% total).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Trichlormethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin."